BIBLIOGRAPHIE

1- Traitement du diabète de type 2: recommandations de bonne pratique. Afssaps/HAS 2006. Diabetes Metabolism ; 32 : 643-8.

2- Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;3:193-203.

3- Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91.

4- Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89. Epub 2008 Sep 10.

5- Bradley C, de Pablos-Velasco P, Parhofer KG, Eschwège E, Gönder-Frederick L, Simon D. PANORAMA: A European study to evaluate quality of life and treatment satisfaction in patients with type-2 diabetes mellitus-Study design. Prim Care Diabetes 2011 Jul 11.

6- Fagot-Campagna A, Fosse S, Roudier C, Romon I, Penfornis A, Lecompte P, et al, pour le comité scientifique Entred. Caractéristiques, risque vasculaire et complications chez les personnes diabétiques en France métropolitaine : d’importantes évolutions entre Entred 2001 et Entred 2007. Bull Epidémiol Hebd 2009 ; (42-4 ») : 450-5.

7- Bouée S, Detournay B, Balkau B, Blicklé JF, Attali C, Vergès B, Avignon A, Halimi S. Diabète de type 2 : pratiques d’intensification thérapeutique chez les médecins généralistes en France en 2008-2009. BEH 42-43 / 9 novembre 2010.

8- Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007 ; 357 : 1716-30.

9- Bolli GB, Gerich JE. The « dawn phenomenon »-a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med 1984; 310: 746-50.

10- Wulfffelé MG, Kooy A, Lehert P, et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002; 25: 2133-40.

11- Lebovitz HE, Pasmentier RM. Combination insulin-sulfonylurea therapy. Diabetes Care 1990; 13: 667-75.

12- Fonseca V, Scweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 1148-55.

13- Govindan JP, Healey B, Kalupahana DN, Singh BM. Exenatide therapy in insulin-treated patients with type 2 diabetes and obesity. Diabetologia 2008; 51 (suppl):S352-S353.

14- Monnier L, Colette C. Addition of rapid-acting insulin therapy in type 2 diabetes : indications and modalities. Diabetes Metab 2006; 32: 7-13.

15- Valensi P, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Wenying Y; IMPROVE Study Group Expert Panel. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract. 2009;63:522-31.

16- Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-67.